184 related articles for article (PubMed ID: 30358858)
1. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
Malczewska A; Bodei L; Kidd M; Modlin IM
J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
[TBL] [Abstract][Full Text] [Related]
2. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
[TBL] [Abstract][Full Text] [Related]
3. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.
Malczewska A; Procner A; Walter A; Kusnierz K; Zajecki W; Aslanian H; Kos-Kudla B
BMC Gastroenterol; 2020 Jul; 20(1):235. PubMed ID: 32703157
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
5. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Modlin IM; Bodei L; Kidd M
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
[TBL] [Abstract][Full Text] [Related]
7. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
9. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
10. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
[TBL] [Abstract][Full Text] [Related]
11. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Modlin IM; Kidd M; Oberg K; Falconi M; Filosso PL; Frilling A; Malczewska A; Salem R; Toumpanakis C; Laskaratos FM; Partelli S; Roffinella M; von Arx C; Kudla BK; Bodei L; Drozdov IA; Kitz A
Ann Surg Oncol; 2021 Nov; 28(12):7506-7517. PubMed ID: 34008138
[TBL] [Abstract][Full Text] [Related]
12. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
13. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
14. A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.
Frilling A; Clift AK; Frampton AE; Bomanji J; Kaemmerer D; Al-Nahhas A; Alsafi A; Kidd M; Modlin IM; Hoersch D; Baum RP
Int J Med Sci; 2021; 18(10):2166-2175. PubMed ID: 33859524
[No Abstract] [Full Text] [Related]
15. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
[TBL] [Abstract][Full Text] [Related]
16. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Malczewska A; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):895-906. PubMed ID: 31838581
[TBL] [Abstract][Full Text] [Related]
17. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
18. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
19. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
20. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
